The hot flushes were manageable, but the stiffness in my hands after sleeping surprised me. Writing down the bad days helped my oncologist take the joint symptoms seriously.
Letrozole, the active ingredient of Femara, is a non-steroidal aromatase inhibitor for hormone-sensitive breast cancer, mainly in postmenopausal women. It lowers oestrogen production and may also be prescribed by fertility specialists for ovulation induction in selected premenopausal women.
Overview
Femara is a prescription medicine containing letrozole as its active ingredient. It belongs to the non-steroidal aromatase inhibitor class and is used in oncology and, under specialist supervision, in reproductive medicine.
Formulation
Femara contains letrozole, a non-steroidal aromatase inhibitor. The tablet is a prescription-only treatment whose suitability depends on the diagnosis, menopausal status, treatment goal and clinical monitoring plan. Letrozole is used in oncology and, under specialist supervision, in reproductive medicine. [1]
Active Ingredient and Pharmaceutical Class
Letrozole belongs to the aromatase inhibitor class. Aromatase is an enzyme that helps convert certain androgens into oestrogen. By inhibiting aromatase, letrozole reduces the amount of oestrogen available to tissues that respond to this hormone.
The Femara tablet is not a general hormone-balancing product. Its effect is pharmacological and can influence bones, joints, mood, menstrual function and fertility. The amount taken per intake is set individually for each person rather than being one fixed number for every use.
Therapeutic indications
Approved Breast Cancer Use
Femara is used mainly for hormone-receptor-positive breast cancer in postmenopausal women. These cancers use oestrogen signals to support their growth, so reducing oestrogen can form part of endocrine treatment.
Menopausal status and hormone-receptor status both matter. Femara does not suit every breast cancer type, and the treatment plan may differ after surgery, after other endocrine treatment, or when cancer has spread. An oncologist decides whether letrozole is appropriate and how long treatment should continue.
Postmenopausal women may receive an aromatase inhibitor as adjuvant treatment after primary breast cancer therapy or as treatment for advanced disease. The exact role depends on pathology, previous treatment and the person’s risk profile.
Specialist Fertility Use
Fertility specialists may use letrozole for ovulation induction in selected premenopausal women with female infertility. This use may be off-label depending on local prescribing practice and the clinical indication.
Ovulation induction requires an individual plan. The clinician may assess menstrual history, pregnancy status, ovarian function, partner factors and the cause of infertility before treatment begins. Cycle monitoring can help identify ovulation, ovarian cysts or a risk of multiple pregnancy.
Dosage and administration
- Dose: Femara tablets are marked 2.5 mg. The prescribed amount per intake is set individually for each person and indication.
- Frequency: For breast cancer, take the prescribed tablet by mouth once daily. For ovulation induction, take it only according to the fertility specialist’s cycle-specific protocol.
- Timing: Take the tablet at a consistent time, with or without food unless the prescriber gives different instructions.
- Duration: Continue for the duration prescribed by the oncologist or fertility specialist; treatment length is individual.
- Route: Swallow the tablet whole with water. Do not crush, split or alter it unless a healthcare professional confirms this is appropriate.
- Missed dose: Do not take two tablets together to compensate unless the prescribing clinician specifically instructs you to do so.
Reasons not to use it
Femara is not suitable for everyone. This medicine is not for you if you have a confirmed allergy to letrozole or an ingredient in the tablet, or if it is being used outside an appropriate clinical indication.
Menopausal Status and Ovarian Function
For breast cancer treatment, Femara is generally intended for postmenopausal women. Age alone does not always establish menopause. Previous chemotherapy, ovarian surgery, hormone treatment and irregular periods can make assessment more complex.
Premenopausal women with breast cancer need an oncologist to assess ovarian function. Concomitant ovarian suppression may be considered in selected cases, but it is not routine for every premenopausal patient.
Pregnancy and Reproductive Potential
Letrozole can harm a developing pregnancy when used outside a supervised fertility protocol. Females of reproductive potential need a clear pregnancy-assessment and contraception plan suited to the treatment indication.
Breastfeeding also requires a specific clinical decision. Letrozole may reduce oestrogen activity and is not generally compatible with unreviewed breastfeeding use.
Bone, Liver and Kidney Considerations
Tell the treating team about osteoporosis, previous fractures, chronic liver disease or kidney impairment. The prescriber may adjust the plan or arrange additional monitoring according to the severity of the condition.
When this is not for you
Femara may not be right for you if you have not been assessed as postmenopausal for breast cancer treatment, could be pregnant, are breastfeeding without medical review, or plan to use it without an appropriate oncology or fertility indication. Tell your healthcare team if you have osteoporosis, previous fractures, liver disease or kidney problems, because these conditions may affect the treatment plan.
Possible side effects
Side effects reflect both the medicine and the reduction in oestrogen. Not every patient experiences the full list, and symptoms can vary in intensity during a long course.
Frequent Oestrogen-Related Effects
Commonly reported effects include:
- Hot flushes and sweating
- Fatigue and reduced energy
- Headache or dizziness
- Nausea or reduced appetite
- Mood changes, irritability or low mood
- Vaginal dryness or reduced sexual interest
- Joint pain and muscle pain
- Stiffness after sitting or waking
Hot flushes may improve with breathable clothing, a cooler bedroom and reduced exposure to personal triggers such as alcohol or very hot drinks. Nausea may be easier to manage with a light meal if the prescriber allows food with the dose.
Joint, Muscle and Bone Symptoms
Aromatase inhibitors can contribute to loss of bone mineral density. The treating team may assess fracture risk and decide whether bone-density testing, calcium and vitamin D review, weight-bearing activity or additional treatment is appropriate.
New back pain after minor strain, loss of height, a wrist injury or a fracture from a low-impact event should be reported promptly. Do not assume that persistent musculoskeletal pain is simply part of ageing.
Urgent Symptoms
Seek prompt medical assessment for:
- Sudden chest pain, breathlessness or coughing blood
- One-sided leg swelling or severe calf pain
- New weakness, speech difficulty or facial drooping
- Severe allergic swelling or breathing difficulty
- Heavy or persistent vaginal bleeding after menopause
- Severe abdominal pain during fertility treatment
- A positive pregnancy test while using letrozole outside a supervised fertility plan
The FDA patient information identifies serious symptoms that require medical attention, while routine effects can often be managed through planned follow-up. [3]
How it affects the body
A simple pathway explains the main action:
Androgens → aromatase enzyme → oestrogen
Letrozole blocks aromatase, so less oestrogen is produced from androgen precursors. It does not remove every source of oestrogen from the body, and its effect differs between postmenopausal breast cancer treatment and temporary fertility protocols. The FDA prescribing information describes letrozole as a potent inhibitor of aromatase activity. [2]
Aromatase Enzyme Inhibition
Aromatase is part of the cytochrome P450 enzyme family. In postmenopausal women, much circulating oestrogen is produced through conversion in peripheral tissues rather than directly from the ovaries. Inhibiting this conversion lowers oestrogen stimulation.
During ovulation induction, the short-term reduction in oestrogen can alter feedback between the brain, pituitary gland and ovaries. This may encourage follicular development in some treatment protocols. Fertility use needs supervision because the response varies from one cycle to another.
Clinical Effects of Lower Oestrogen
Lower oestrogen explains several common effects of letrozole. Hot flushes, sweating, vaginal dryness, reduced libido, tiredness, joint stiffness and bone loss can resemble symptoms of menopause.
The same hormone reduction that supports endocrine treatment can create burdensome symptoms. A patient who develops persistent joint pain, worsening mobility or a new fracture should report it to the treating team rather than quietly stopping treatment.
Common mistakes
Common Patient Mistakes
- Taking a fertility schedule without confirming the correct cycle day
- Doubling a tablet after a missed dose
- Stopping long-term breast cancer treatment abruptly because joint pain develops
- Ignoring a new fracture or persistent vaginal bleeding
- Treating hormone creams, supplements or herbal products as unrelated
- Assuming that a 2.5 mg tablet is suitable for every indication
- Using age alone to decide whether menopause has occurred
Comparison
Letrozole, tamoxifen and clomiphene citrate act on oestrogen pathways but have different roles. The best choice depends on the condition being treated, menopausal status, ovarian function, body mass index, cancer history, ovarian reserve and pregnancy goals.
| Medicine | Main mechanism and clinical role | Main limitation |
|---|---|---|
| Letrozole | Aromatase inhibition; breast cancer endocrine therapy and specialist ovulation induction | Oestrogen-related symptoms, joint effects and bone-health concerns |
| Tamoxifen | Selective oestrogen-receptor modulation; endocrine treatment for breast cancer in several menopausal settings | Thromboembolic and uterine risks require assessment |
| Clomiphene citrate | Selective oestrogen-receptor modulation for ovulation induction | May cause visual symptoms, ovarian enlargement and a higher multiple-pregnancy risk than some alternatives |
Letrozole and Clomiphene Citrate
Clomid is a brand name for clomiphene citrate. Both clomiphene citrate and letrozole may be used for ovulation induction, but they stimulate the reproductive system through different mechanisms.
Treatment selection depends on the cause of anovulation and the person’s reproductive history. Letrozole may be chosen in some patients with polycystic ovary syndrome, while clomiphene citrate may remain suitable in other situations. Neither medicine guarantees pregnancy, and pregnancy outcomes depend on ovulation, sperm factors, tubal factors, age and other clinical variables.
Letrozole and Tamoxifen
Tamoxifen is an antiestrogen therapy that blocks or modifies oestrogen-receptor signalling in tissues. It may be used for breast cancer in premenopausal or postmenopausal women, depending on the clinical situation.
Letrozole reduces oestrogen production rather than mainly blocking the receptor. It is commonly used after menopause or alongside ovarian suppression when an oncologist considers that approach appropriate. Tamoxifen and letrozole are not interchangeable, and sequential treatment requires a planned schedule.
What doctors say
Doctor Perspectives
Clinicians usually set expectations early: letrozole can be useful, but the benefit is linked to the correct indication and regular follow-up. An oncologist may discuss treatment duration, menopausal status, recurrence risk, bone density and the management of joint symptoms.
A fertility specialist may explain that ovulation induction is a cycle-based process. The first plan may need adjustment after the response is assessed, and the absence of pregnancy in one cycle does not show that every future option will fail.
Medsafe and the EMA describe letrozole within a structured prescribing framework, rather than as a self-directed hormone treatment. [4]
Comparison
Common questions
How long does a Femara course last, and is long-term use acceptable?
The duration depends on the indication, response and risk assessment. Breast cancer treatment may continue for several years under oncology supervision, while ovulation induction usually follows a limited cycle-based protocol. NICE guidance updated in 2024 supports planned endocrine treatment and follow-up rather than self-selected treatment duration. Long-term use requires review of bone health, symptoms and the continuing balance between benefit and risk. Follow-up timing should be agreed with the oncology or fertility team.
Can Femara be combined with tamoxifen or supplements?
Tamoxifen, oestrogen-containing products and hormone treatments need review before combination or switching. Vitamins and herbal supplements should also be disclosed because they may affect treatment planning or contain hormone-active ingredients. Medsafe (2022) medicine-safety information supports a complete medicine reconciliation before prescribing. Do not start a supplement or hormone product without telling the treating clinician.
Is Femara suitable for older adults?
Older adults may use letrozole when the indication is appropriate, but age does not remove the need to assess kidney function, liver function, bone density, falls and other medicines. The EMA (2023) product information supports individual assessment rather than an automatic age-based exclusion. A clinician may pay closer attention to dizziness, fractures, mobility and interactions in an older person. The same tablet strength does not mean the same treatment plan for every patient.
What happens when Femara is stopped, and does it need tapering?
Letrozole is not usually tapered in the way some medicines are, but the stopping plan depends on why it was prescribed. Stopping breast cancer treatment without oncology guidance may remove intended endocrine protection, while stopping a fertility protocol may change the cycle plan. The WHO Model List framework published in 2023 supports indication-based prescribing and planned follow-up for medicines with significant clinical effects. Tell the treating team before stopping, especially after persistent side effects or a possible pregnancy.
Can Femara be taken with food or on an empty stomach?
Femara tablets can generally be taken with or without food, provided the prescribed directions are followed consistently. Food may help a person who experiences nausea, but it does not make an unsuitable dose appropriate. The FDA (2024) prescribing information for letrozole describes oral administration without requiring a special meal pattern. Taking the tablet at the same time each day can make adherence easier.
What should be discussed with a doctor before starting Femara?
Discuss the reason for treatment, menopausal status, pregnancy possibility, breastfeeding, osteoporosis, fractures, liver or kidney disease and every medicine or supplement being used. Breast cancer patients should also discuss hormone-receptor results and previous endocrine treatment; fertility patients should discuss cycle history, pregnancy testing and monitoring. Medsafe’s 2022 medicine-safety principles support sharing relevant medical history before a prescription medicine is started. The treatment plan should be clear before the first tablet is taken.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Sources
- U.S. Food and Drug Administration (2024). Femara (letrozole) Prescribing Information
- U.S. Food and Drug Administration (2018). Femara Clinical Pharmacology and Prescribing Information
- U.S. Food and Drug Administration (2024). Femara Medication Guide
- European Medicines Agency (2023). Letrozole: Summary of Product Characteristics
Reviews: Femara
The clinic explained the timing carefully and arranged follow-up. I had headaches for a few days, and the cycle did not result in pregnancy, so I appreciated having a review rather than simply repeating the tablets.
I noticed less energy and some pelvic discomfort around the time of monitoring. The process felt organised, but it was emotionally difficult when the first cycle did not work.
The medicine fitted into my morning routine, although my knees became sore after sitting. Gentle movement helped, but I needed a treatment review when walking became uncomfortable.